{
    "nct_id": "NCT05389215",
    "official_title": "A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of DWN12088 in Patients With Idiopathic Pulmonary Fibrosis",
    "inclusion_criteria": "* Male or female patients aged ≥40 years based on the date of the written informed consent form\n* Diagnosis of IPF as defined by American Thoracic Society/European Respiratory Society/Japanese Respiratory Society/Latin American Thoracic Association guidelines\n* In a stable condition and suitable for study participation based on the results of medical history, physical examination, vital signs, 12-lead ECG, and laboratory evaluation\n* Patients receiving local standard-of-care for IPF, defined as either pirfenidone or nintedanib, at a stable dose for at least 3 months prior to screening, or neither pirfenidone nor nintedanib. If the patients were on pirfenidone or nintedanib previously and have been off for at least 3 months prior to screening, they will be considered as not on any treatment for IPF\n* Meeting all of the following criteria during the screening period:\n\n  * FVC ≥40% predicted of normal\n  * DLCO corrected for Hgb ≥25% and ≤80% predicted of normal.\n  * forced expiratory volume in the first second/FVC (FEV1/FVC) ratio ≥0.7 based on pre-bronchodilator value\nHealthy volunteers allowed\nMust have minimum age of 40 Years",
    "exclusion_criteria": "* Acute IPF exacerbation within 6 months prior to screening and/or during the screening period\n* Patients who are unwilling to refrain from smoking within 3 months prior to screening and until the end of the study\n* Female patients who are pregnant or nursing\n* Abnormal ECG findings\n* Use of any investigational drugs for IPF within 4 weeks prior to screening",
    "miscellaneous_criteria": ""
}